Monday, September 14, 2020 5:26:15 PM
976TiP - SPEARHEAD-2 trial design: A phase II pilot trial of ADP-A2M4 in combination with pembrolizumab in patients with recurrent or metastatic head and neck cancer
Background
ADP-A2M4 SPEAR T-cells are genetically engineered to target MAGE-A4+ tumors in HLA-A*02 positive patients (pts). Safety and efficacy for ADP-A2M4 cells have been demonstrated in a phase I trial (NCT03132922). MAGE-A4 is frequently expressed in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). Pembrolizumab (pembro), an anti-PD-1 checkpoint inhibitor, monotherapy is approved as 1st-line treatment of r/m HNSCC that expresses PD-L1. The combination of ADP-A2M4 and pembro may result in a synergistic effect due to the inhibition of PD-1 on ADP-A2M4 cells potentially leading to deeper and more durable anti-tumor responses.
Trial design
This single-arm trial will enroll up to 10 pts to evaluate efficacy, safety, and tolerability of ADP-A2M4 with pembro. Checkpoint inhibitor naïve r/m HNSCC pts who are HLA-A*02, MAGE-A4+, and PD-L1 positive (≥1%) will be eligible. Part A is a run-in-phase with pembro as standard-of-care monotherapy followed by Part B, an interventional phase, during which ADP-A2M4 will be administered with pembro post-ADP-A2M4 infusion in patients without response or following progressive disease (PD) with pembro in Part A. Part A: Pts will undergo leukapheresis, and collected T-cells will be transduced with a Lentiviral vector expressing a high affinity MAGE-A4 specific T-cell receptor. Pts will receive pembro monotherapy (200 mg IV) every 3 weeks for a minimum of 3 cycles. Disease status will be assessed at Wk 7. Pts without a response by Wk 7 will proceed to Part B. Pts who respond to pembro after 3 cycles will continue treatment in Part A until PD when they will become eligible for ADP-A2M4 treatment in Part B. Part B: Pts will undergo lymphodepleting chemotherapy w/ fludarabine and cyclophosphamide prior to receiving ADP-A2M4 at a dose range of 1x109 to 10x109 transduced T-cells. Pembro infusions every 3 weeks will re-start after ADP-A2M4 infusion and will continue until PD. A Safety Review Committee will review safety and benefit:risk during Part B. Disease will be assessed by investigators per RECIST v1.1 using CT/MRI scans post T-cell infusion.
Clinical trial identification
NCT03132922.
Recent ADAP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 08:15:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 11:23:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:05:55 AM
- U.S. Futures Steady as Markets Await Key Inflation Data, Oil Prices Climb • IH Market News • 08/12/2024 09:47:41 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 11:00:19 AM
- Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor • Business Wire • 08/02/2024 12:20:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:30:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:39:58 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:14:55 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:34:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:13:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:05:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:07:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:31:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:30:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:02:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:02:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:00:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:46:16 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM